Korro Bio, Inc. (KRRO) NASDAQ
12.68
-0.4(-3.06%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
12.68
-0.4(-3.06%)
Currency In USD
Address
One Kendall Square
Cambridge, MA 02139-1562
United States of America (the)
Phone
781-315-4600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
112
First IPO Date
October 03, 2019
| Name | Title | Pay | Year Born |
| Ram Aiyar | Chief Executive Officer, President, Interim Chief Financial Officer, Principal Financial Officer & Director | 939,075 | 1978 |
| Loic Vincent | Chief Scientific Officer | 592,895 | N/A |
| Jeffrey Cerio | Senior VP, General Counsel & Corporate Secretary | 615,025 | N/A |
| Kemi Olugemo | Chief Medical Officer | 649,724 | 1977 |
| Olukemi A. Olugemo | Advisor | 649,724 | 1976 |
| Andrew Fraley | Co-Founder & Advisor | 0 | N/A |
| Joshua Rosenthal | Co-Founder & Advisor | 0 | N/A |
| Gaozhong Zhu | SVP of Chemistry, Manufacturing and Controls & Technical Operations | 0 | N/A |
| Venkat Krishnamurthy | Senior Vice President & Head of Platform | 0 | N/A |
| Oliver Dolan | Senior VP of Finance & Principal Accounting Officer | 0 | 1983 |
| Todd Chappell | Chief Operating Officer | 0 | 1973 |
| Stephanie Engels | Chief People Officer | 0 | N/A |
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.